Search research articles
Contact Us
Filters
Showing results (41-50 of 153) with videos related to
Page
of 16
Sort By:
Clinical Genitourinary Cancer
|
May 4, 2017
Consolidative Radiotherapy in Metastatic Urothelial Cancer
Sumit Shah, Chiyuan Amy Zhang, Steven Hancock, et al.
Cancer Investigation
|
July 16, 2009
Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma
Lauren C Harshman, Calvin J Kuo, Bryan Y Wong, et al.
BJU International
|
May 5, 2010
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients
Lauren C Harshman, Gerold Bepler, Zhong Zheng, et al.
Current Medical Research and Opinion
|
July 13, 2016
The effect of information on preferences for treatments of metastatic renal cell carcinoma
Carol Mansfield, Sandy Srinivas, Connie Chen, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
November 19, 2013
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Leslie Wilson, Jun Tang, Lixian Zhong, et al.
Urology
|
June 13, 2006
Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
Christopher R King, John E McNeal, Harcharan Gill, et al.
JACC. Cardiooncology
|
August 16, 2021
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Sarah Waliany, Kristin L Sainani, Lesley S Park, et al.
Urologic Oncology
|
March 1, 2011
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)
Lauren C Harshman, R James Yu, Genevera I Allen, et al.
Plos One
|
May 30, 2013
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis
Lixian Zhong, Vickie Pon, Sandy Srinivas, et al.
Investigational New Drugs
|
February 26, 2013
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Robert Dreicer, Jorge Garcia, Brian Rini, et al.
Page
of 16
Search research articles
Search
Showing results (41-50 of 153) with videos related to
Sort By:
Page
of 16
Clinical Genitourinary Cancer
|
May 4, 2017
Consolidative Radiotherapy in Metastatic Urothelial Cancer
Sumit Shah, Chiyuan Amy Zhang, Steven Hancock, et al.
Cancer Investigation
|
July 16, 2009
Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma
Lauren C Harshman, Calvin J Kuo, Bryan Y Wong, et al.
BJU International
|
May 5, 2010
Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients
Lauren C Harshman, Gerold Bepler, Zhong Zheng, et al.
Current Medical Research and Opinion
|
July 13, 2016
The effect of information on preferences for treatments of metastatic renal cell carcinoma
Carol Mansfield, Sandy Srinivas, Connie Chen, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
November 19, 2013
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Leslie Wilson, Jun Tang, Lixian Zhong, et al.
Urology
|
June 13, 2006
Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade
Christopher R King, John E McNeal, Harcharan Gill, et al.
JACC. Cardiooncology
|
August 16, 2021
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Sarah Waliany, Kristin L Sainani, Lesley S Park, et al.
Urologic Oncology
|
March 1, 2011
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)
Lauren C Harshman, R James Yu, Genevera I Allen, et al.
Plos One
|
May 30, 2013
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis
Lixian Zhong, Vickie Pon, Sandy Srinivas, et al.
Investigational New Drugs
|
February 26, 2013
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Robert Dreicer, Jorge Garcia, Brian Rini, et al.
Page
of 16